相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel
Jolanta M. Siller-Matula et al.
AMERICAN HEART JOURNAL (2009)
Advances in Antiplatelet Therapy: Agents in Clinical Development
Dominick J. Angiolillo et al.
AMERICAN JOURNAL OF CARDIOLOGY (2009)
Rationale and Design of the Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study
Michael G. Hennerici
CEREBROVASCULAR DISEASES (2009)
TP Receptor Antagonism: A New Concept in Atherothrombosis and Stroke Prevention
Angel Chamorro
CEREBROVASCULAR DISEASES (2009)
Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779
J. L. Diener et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial
Gilles Montalescot et al.
LANCET (2009)
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study
Richard C. Becker et al.
LANCET (2009)
Ticagrelor - Is There Need for a New Player in the Antiplatelet-Therapy Field?
Albert Schoemig
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Inhibition of platelet aggregation with prasugrel and clopidogrel: An integrated analysis in 846 subjects
Ying G. Li et al.
PLATELETS (2009)
The aptamer ARC1779 is a potent and specific inhibitor of von willebrand factor mediated ex vivo platelet function in acute myocardial infarction
Alexander O. Spiel et al.
PLATELETS (2009)
The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation
Jolanta M. Siller-Matula et al.
THROMBOSIS RESEARCH (2009)
Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura
Paul Knoebl et al.
TRANSFUSION (2009)
Future innovations in anti-platelet therapies
N. E. Barrett et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Guide to receptors and channels (GRAC), 3rd edition
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38
Stephen D. Wiviott et al.
CIRCULATION (2008)
Von Willebrand factor in cardiovascular disease focus on acute coronary syndromes
Alexander O. Spiel et al.
CIRCULATION (2008)
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial
Sabina A. Murphy et al.
EUROPEAN HEART JOURNAL (2008)
Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans
Nagy A. Farid et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity
Samuel Chackalamannil et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Basic and Translational Research on Proteinase-Activated Receptors: Antagonism of the Proteinase-Activated Receptor 1 for Thrombin, a Novel Approach to Antiplatelet Therapy for Atherothrombotic Disease
Madhu Chintala et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2008)
Calcium-Channel Blockers Reduce the Antiplatelet Effect of Clopidogrel
Jolanta M. Siller-Matula et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
The reversible P2Y12 antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function
N. L. Dovlatova et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
The active metabolite of prasugrel effectively blocks the platelet P2Y(12) receptor and inhibits procoagulant and pro-inflammatory platelet responses
Heather M. Judge et al.
PLATELETS (2008)
Novel P2Y(12) adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): Pharmacodynamic and pharmacokinetic characterization
Joseph M. Post et al.
THROMBOSIS RESEARCH (2008)
Novel P2Y(12) adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): In vitro effects on platelets
Judi Bryant et al.
THROMBOSIS RESEARCH (2008)
Transitioning patients from cangrelor to clopidogrel: Pharmacodynamic evidence of a competitive effect
Steven R. Steinhubl et al.
THROMBOSIS RESEARCH (2008)
Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future
Nina C. Raju et al.
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE (2008)
Prasugrel achieves greater and faster P2Y(12) receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
Lars Wallentin et al.
EUROPEAN HEART JOURNAL (2008)
The selective TP receptor antagonist, S18886 (Terutroban), attenuates renal damage in the double transgenic rat model of hypertension
Katarina Sebekova et al.
AMERICAN JOURNAL OF NEPHROLOGY (2008)
Novel uses for anti-platelet agents as anti-inflammatory drugs
S. C. Pitchford
BRITISH JOURNAL OF PHARMACOLOGY (2007)
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention - The prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial
Stephen D. Wiviott et al.
CIRCULATION (2007)
First-in-human evaluation of anti-von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers
James C. Gilbert et al.
CIRCULATION (2007)
Prasugrel: A novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile
Joseph A. Jakubowski et al.
CARDIOVASCULAR DRUG REVIEWS (2007)
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Stephen D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Safety, tolerability, and initial efficacy of AZD6140, the first reversivle oral adenosine diphosphate receptor antagonist, compared with clopidigrel, in patients with non-ST-segment elevation acute coronary syndrome - Primary results of the DISPERSE-2 trial
Christopher P. Cannon et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Inhibition of platelet aggregation by AZD6140, A reversible oral P2Y12 receptor antagonist, compared with clopidogral in patients with acute coronary syndrome
Robert F. Storey et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel
Christopher D. Payne et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2007)
Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction:: Results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial
Adam B. Greenbaum et al.
AMERICAN HEART JOURNAL (2007)
The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite
A. Sugidachi et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
The disposition of prasugrel, a novel thienopyridine, in humans
Nagy A. Farid et al.
DRUG METABOLISM AND DISPOSITION (2007)
Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently
N. A. Farid et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Renal effects of S18886 (Terutroban), a TP receptor antagonist, in an experimental model of type 2 diabetes
Katarina Sebekova et al.
DIABETES (2007)
A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans
Joseph A. Jakubowski et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
AZD6140
Udaya S. Tantry et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation
John T. Brandt et al.
AMERICAN HEART JOURNAL (2007)
Preclinical evaluation of S18886 in an experimental model of coronary arterial thrombosis
Ting-Ting Hong et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2006)
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis:: a double-blind comparison to clopidogrel with aspirin
S Husted et al.
EUROPEAN HEART JOURNAL (2006)
Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450
JLF Rehmel et al.
DRUG METABOLISM AND DISPOSITION (2006)
Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention:: Results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial
AB Greenbaum et al.
AMERICAN HEART JOURNAL (2006)
The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies
P Gaussem et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Randomized comparison of Prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention -: Results of the joint utilization of medications to block platelets optimally (JUMBO)-TIMI 26 trial
SD Wiviott et al.
CIRCULATION (2005)
Preclinical and clinical studies with selective reversible direct P2Y12 antagonists
JJJ van Giezen et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2005)
Pharmacology of CS-747 (Prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity
Y Niitsu et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2005)
In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability
MA van Gestel et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2003)
Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model
K Wang et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2003)
Platelets and anti-platelet therapy
A McNicol et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2003)
Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease
RF Storey et al.
PLATELETS (2002)
Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction
F Jacobsson et al.
CLINICAL THERAPEUTICS (2002)
Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys
S Kageyama et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2002)
The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties
A Sugidachi et al.
BRITISH JOURNAL OF PHARMACOLOGY (2000)
分享论文
